On March 9, 2023 Herantis Pharma Plc ("Herantis"), developing disease-modifying therapies for Parkinson’s disease, reported participation in the following conferences (Press release, Herantis Pharma, MAR 9, 2023, View Source,c3730042 [SID1234628382]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bio-Europe Spring
Location: Basel, Switzerland
Dates: March 20th – 22nd, 2023
Attendees: CEO Antti Vuolanto, DSc and CSO Dr. Henri Huttunen, PhD
AD/PD 2023: International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders
Location: Gothenburg, Sweden
Dates: March 28th – April 1th, 2023
Poster Presentation by Head of Nonclinical Pharmacology at Herantis, Natalia Kulesskaya, PhD.
Title: HER-096 Is a Novel Brain-Penetrating Peptidomimetic That Promotes Proteostasis and Reduces Neuroinflammation in Aged Mouse Model of Synucleinopathy
Presentation by Per Svenningsson, MD, PhD, Karolinska University Hospital, Principal Investigator of Herantis’ CDNF in the First-in-Human Clinical Trial.
Title: Phase 1 First-in-Man Clinical Trial of Intraputamenal CDNF in Parkinson’s Disease
If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us directly at [email protected].
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: [email protected]
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225